Skip to main content
SpringerLink
Log in

Eliciting health state utilities from the general public for severe chronic pain

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objective

There is an absence of data on public preferences for health states (HSs) associated with severe chronic pain. The aim of this study was to develop accurate HS descriptions for severe chronic pain requiring intrathecal (IT) therapy and to derive utility weights that describe the health-related quality of life (HRQL) impact of chronic pain associated with malignant (MP) and non-malignant (NMP) aetiologies.

Research design and method

Eight visual analogue scale pain index (VAS-PI) HSs were defined using ranges 0–40, 41–60, 61–80 and 81–100 applied to both MP and NMP. Additionally, eight HSs representing common adverse events associated with IT therapy were identified. The content and description of the HSs were ascertained by interviews with five United Kingdom clinical experts. In total, 16 HSs were compiled. These HS descriptions and HS questionnaires were administered to 102 members of the public, utilising a time trade off (TTO) approach to estimate utilities for the HSs.

Results

Participants generally were well matched to the general public in England and Wales, with some differences in mean age, race and education. A substantial decline in utility was observed with more severe VAS-PI values. The mean TTO utility values also decreased from mild pain to severe pain. Participants were able to differentiate between the side effects.

Conclusion

The study shows a clear decrement in utility moving from different severity levels of severe chronic pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gureje, O., Von Korff, M., Simon, G.E., Gater, R.: Persistent pain and well-being: a world health organization study in primary care. JAMA 280, 147–151 (1998)

    Article  Google Scholar 

  2. Smith, B.H., Elliott, A.M., Chambers, W.A., Smith, W.C., Hannaford, P.C., Penny, K.: The impact of chronic pain in the community. Fam. Pract. 18, 292–299 (2001)

    Article  Google Scholar 

  3. Elliott, A.M., Smith, B.H., Hannaford, P.C., Smith, W.C., Chambers, W.A.: The course of chronic pain in the community: results of a 4-year follow-up study. Pain 99, 299–307 (2002)

    Article  Google Scholar 

  4. Turner, J.A., Sears, J.M., Loeser, J.D.: Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin. J. Pain. 23, 180–195 (2007)

    Article  Google Scholar 

  5. Williams, J.E., Louw, G.: Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol. Assess. 4, 1–65 (2000)

    Google Scholar 

  6. Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)

    Article  Google Scholar 

  7. Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based single index measure for health from the SF-36. J. Health Econ. 21, 271–292 (2002)

    Article  Google Scholar 

  8. McDermott, A.M., Toelle, T.R., Rowbotham, D.J., Schaefer, C.P., Dukes, E.M.: The burden of neuropathic pain: results from a cross-sectional survey. Eur. J. Pain 10, 127–135 (2006)

    Article  Google Scholar 

  9. Ackerman, L.L., Follet, K.A.: Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J. Pain Symptom Manage. 26, 668–677 (2003)

    Article  Google Scholar 

  10. Anderson, A., Burchiel, K.: A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 44, 289–300 (1999)

    Article  Google Scholar 

  11. Nitescu, P., Dahm, P., Appelgren, L., Curelaru, I.: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of “refractory” nonmalignant pain. J. Clin. Pharm. 14, 17–28 (1998)

    Google Scholar 

  12. Sjöberg, M., Nitescu, P., Appelgren, L., Curelaru, I.: Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 80, 284–297 (1994)

    Article  Google Scholar 

  13. Winkelmüller, M., Winkelmüller, W.: Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J. Neurosurg. 85, 458–467 (1996)

    Article  Google Scholar 

  14. Carlsson, A.M.: Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 16, 87–101 (1997)

    Article  Google Scholar 

  15. Price, D.D., McGrath, P.A., Rafii, A., Buckingham, B.: The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17, 45–56 (1983)

    Article  Google Scholar 

  16. Rauck, R.L., Wallace, M.S., Leong, M.S., Minehart, M., Webster, L.R., Charapata, S.G., Abraham, J.E., Buffington, D.E., Ellis, D., Kartzinel, R.: Ziconotide 301 Study Group: a randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. 31, 393–406 (2006)

    Article  Google Scholar 

  17. Staats, P.S., Yearwood, T., Charapata, S.G., Presley, R.W., Wallace, M.S., Byas-Smith, M., Fisher, R., Bryce, D.A., Mangieri, E.A., Luther, R.R., Mayo, M., McGuire, D., Ellis, D.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291, 63–70 (2004)

    Article  Google Scholar 

  18. Wermeling, D., Drass, M., Ellis, D., Mayo, M., McGuire, D., O’Connell, D., Hale, V., Chao, S.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol. 43, 624–636 (2003)

    Google Scholar 

  19. Atanassoff, P.G., Hartmannsgruber, M.W., Thrasher, J., Wermeling, D., Longton, W., Gaeta, R., Singh, T., Mayo, M., McGuire, D., Luther, R.R.: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg. Anesth. Pain. Med. 25, 274–278 (2000)

    Google Scholar 

  20. Brose, W.G., Gutlove, D.P., Luther, R.R., Bowersox, S.S., McGuire, D.: Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin. J. Pain 13, 256–259 (1997)

    Article  Google Scholar 

  21. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D.: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10, 287–333 (2006)

    Article  Google Scholar 

  22. Kamran, S., Wright, B.: Complications of intrathecal drug delivery systems. Neuromodulation 4, 111–115 (2001)

    Article  Google Scholar 

  23. Mercadante, S.: Controversies over spinal treatment in advanced cancer patients. Support. Care Cancer 6, 495–502 (1998)

    Article  Google Scholar 

  24. Naumann, C., Erdine, S., Koulousakis, A., Van Buyten, J.P., Schuchard, M.: Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation 2, 92–107 (2002)

    Article  Google Scholar 

  25. Tutak, U., Doleys, D.M.: Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med. J. 89, 295–300 (1996)

    Article  Google Scholar 

  26. Yang, C.Y., Wong, C.S., Chang, J.Y., Ho, S.T.: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can. J. Anaesth. 43, 379–383 (1996)

    Article  Google Scholar 

  27. Wallace, M.S., Rauck, R., Fisher, R., Charapata, S.G., Ellis, D., Dissanayake, S., Ziconotide 98-022 Study Group: Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth. Analg. 106, 628–637 (2008)

    Article  Google Scholar 

  28. Wermeling, D.P., Berger, J.R.: Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy 26, 395–402 (2006)

    Article  Google Scholar 

  29. Kind, P.: The EuroQoL instrument: an index of health-related quality of life. In: Spilker, B. (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials, pp. 191–203. Lippincott-Raven, Philadelphia (1996)

    Google Scholar 

  30. The EuroQol Group: EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990)

    Google Scholar 

  31. Bennett, K., Torrance, G.: Measuring health state preferences and utilities: Rating scale, time trade-off and standard gamble techniques. In: Spilker, B. (ed.) HRQL and Pharmacoeconomics in Clinical Trials, pp. 253–266. Lippincott-Rave, Philadelphia (1996)

    Google Scholar 

  32. National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal. http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf (2004)

  33. National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (2008)

  34. Lai, K.C., Provenzale, J.M., Delong, D., Mukundan, S, Jr: Assessing patient utilities for varying degrees of low back pain. Acad. Radiol. 12, 467–474 (2005)

    Article  Google Scholar 

  35. Roland, M., Morris, R.: A study of the natural history of low-back pain. Part II: development of guidelines for trials of treatment in primary care. Spine 8, 145–150 (1983)

    Article  Google Scholar 

  36. Roland, M., Morris, R.: A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine 8, 141–144 (1983)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pain and Anaesthesia, The James Cook University Hospital, Middlesbrough, UK

    S. Eldabe

  2. Former United BioSource Corporation, London, UK

    A. Lloyd & S. Dewilde

  3. Eisai Global Health Economics and Outcomes Research, London, UK

    L. Verdian & G. Maclaine

  4. United BioSource Corporation, London, UK

    M. Meguro

Authors
  1. S. Eldabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Verdian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Meguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Maclaine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Dewilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Verdian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eldabe, S., Lloyd, A., Verdian, L. et al. Eliciting health state utilities from the general public for severe chronic pain. Eur J Health Econ 11, 323–330 (2010). https://doi.org/10.1007/s10198-009-0178-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-009-0178-x

Keywords

JEL Classification

Search

Navigation